90 Day
BPC-157 Peptide Injections for Soft Tissue Recovery
| STUDY TITLE | BPC-157 Peptide Injections for Soft Tissue Recovery |
|---|---|
| Submitted under umbrella | |
| Date submitted |
- |
| End date |
There is no pre-specified end date and sub-studies remain open long-term. |
| Language |
English |
| Efforia AI IRB approval recommendation | |
| Recruitment page preview | |
| Author edit | |
| Informed consent | |
| Study author |
Greg Henderson |
| Principal investigator |
Matthew Amsden |
| Sub-Investigator for Adverse Events |
Dr. Viral Patel |
| Description |
Participants with acute soft tissue injuries will self-administer BPC-157 peptide injections. The focus is on improving recovery and reducing pain levels. |
| Participant engagement length |
90 Days |
| Sponsor |
This study is made possible by your payment to cover all supplies and expenses required to participate. |
| Cost to participant |
$0 |
| Included products & services | |
| Outcome measures |
PROMIS Physical Function – Short Form 10a Survey ROMIS® Numeric Rating Scale v.1.0 – Pain Intensity 1a |
| Methodology |
Single Arm longitudinal where participants act as their own control |
| Basic or advanced dissemination plan |
Basic |
| Deviation from recruitment approach |
No |
| Deviation from statistical approach |
No |
| Will study include “more about you questions” |
No |
| Clinicaltrials.Gov |
Yes |
| Committment to list findings on clinicaltrials.Gov |
Yes |
Preview This document is prepared with the assistance of AI, but is reviewed by a human.
Rational & Study Design
Why I am running this study:
Acute soft tissue injuries are common, affecting millions and often leading to prolonged recovery and persistent pain. BPC-157, a peptide reported in social media and some studies, shows promise in enhancing recovery and reducing pain. While anecdotal evidence abounds on platforms like Instagram and TikTok, scientific validation is limited. Scholarly research suggests potential benefits, yet comprehensive clinical trials are scarce. This protocol aims to bridge the gap between anecdotal claims and scientific evidence, providing a rigorous assessment of BPC-157's efficacy in real-world settings. By evaluating outcomes with validated measures like the PROMIS Physical Function Survey and the ROMIS® Pain Intensity Scale, we aim to provide clarity and potentially a new therapeutic avenue for those experiencing these injuries.
My Objective for You:
Our primary goal is to empower you to take charge of your recovery journey from acute soft tissue injuries. By participating in this study, you'll gain insights into how BPC-157 peptide injections might enhance your physical function and reduce pain. We aim to offer a personalized approach to accelerate your healing process, allowing you to return to your daily activities with improved quality of life.
Aims & Objectives:
This study aims to evaluate the efficacy of self-administered BPC-157 peptide injections in improving physical function and reducing pain in individuals with acute soft tissue injuries. Our objective is to generate robust data that informs both clinical practice and individual recovery strategies.
Significance & Impact:
The significance of this study lies in its potential to offer a novel treatment pathway for acute soft tissue injuries. Expected outcomes include improved recovery times and reduced pain levels, contributing to enhanced quality of life. However, limitations include the variability in individual responses and adherence to self-administration protocols. By addressing these, we aim to provide meaningful insights that could redefine management strategies for soft tissue injuries.